Chain Drug Review

View more issues:

Articles in April 28, 2008 issue of Chain Drug Review

• Positive signs proliferate at drugstore.com
• Publicly held drug chains: their five-year track records
• CMS asked to scrap definition
• Members gain clout via CDC
• Rx must take part in national debate
  by Steve Anderson
• Bodine plans to retire in '09
• Walgreens promotes Rosenbluth
• Top chains face tough challenges
  by David Pinto
• Changes continue in Duane Reade top ranks
• Medi-Cal reductions come under scrutiny
• HIV/AIDS focus of new web site
• NACDS steps up for pharmacy
• Rite Aid, Fuji partner on imaging business
• Cardinal offers fix for health care system
• HDMA releases 'Blueprint for Data Management'
• Caremark's Crawford starts new venture
• More clinics are in works at Rite Aid
• Maher is joining Pharmaca board
• Two key positions filled by Pharmavite
• AG names senior VP, marketing
• Voots targets 'nutritional gap'
• More options added to Halls
• Church & Dwight will buy Del Pharmaceuticals
• FGX appoints Kornhauser
• SONA provides 'actionable insights'
• Alagio launches Trend Starter
• InstaKool gets ready to go mass
• Nutrition 21 tabs interim leaders
• At-home paternity test kit debuts
• Integrated BioPharma evolves
• Sally Hansen's Natural Beauty
• Hershey's Bliss is life of the party
• Promax expands offerings with line of protein bars
• Revlon adds spokeswoman
• New reading glass line goes green
• Tight cost controls help Walgreens top expectations
• March sales advance at drug chains
• Rx services pivotal part of strategy
• Chain drug stocks outperform market
• Duane Reade EBITDA advances in fourth quarter, year
• Further progress is anticipated
• Acquisition costs, tax charge take big toll at Rite Aid
• Another loss seen for FY '09
• Drug store suppliers have mixed quarter
• Health Mart acts as catalyst in Rx market
  by Jeffrey Woldt
• Chain drug world changes
  by David Pinto
• The era of retail megamergers may be over
• Economic outlook for '08 is uncertain
• Fed steps in to avert disaster
• Credit crisis may be far from over
• Drug chains are on safe ground
• M&As take on different aspect
• Demographic trends are favorable for industry
• Rosy future awaits generic drug suppliers
• Top 50 drug chains by dollar volume
• Top 50 drug chains by store count
• NACDS a catalyst in the evolution of chain pharmacy
• Foundation upping the ante
• Project Destiny looks at what's ahead for Rx
• Bryant aims to keep industry focused on the customer
• Anderson makes NACDS a more effective advocate
• Community pharmacy arrives at a turning point
• In-store health clinics are important part of equation
• Generics discount plans spur price competition
• PBMs wield considerable clout in Rx marketplace
• Mail-order option wins more adherents
• Work sites hospitable environment for retail pharmacies
• Medicaid policy a battleground
• Community Rx groups seek legislative relief
• Burden on states may grow
• Increases in dispensing fees are sought
• Medicare Part D is a big hit with beneficiaries
• Retail Rx takes leading role in MTM implementation
• Once again, dispensing fees at issue
• Discounters feel the pinch
• Doubts about Sears mount
• Trade class succeeds in shaking up generic drug pricing
• Food/drug combos lose some of their luster
• 'A gleaming example of innovation'
• Role of Rx in channel evolves

• 1
• 2
• 3
• 4
• 5